mexican pharma market,cro of latam

Clinical Trials in: Mexico, Argentina, Colombia and Brazil.

Locally-Based, Full Service CRO

Contact us today to learn more.

+ 0
Sites Throughout LATAM
+ 200
Patients in our network
+ 0
Conducted Studies
0 %
Lost-to-Follow Up rate
pharma
Global pharma companies are turning their focus to Mexico, with its low manufacturing costs and proximity to the US as two of the major advantages.

Cohortias the CRO of LATAM - Mexican pharma market growth factors and advantages

Mexico is Latin America’s second-largest pharmaceutical market and ranks in the top 15 on the global list of biggest pharma markets. By 2025, multiple growth factors are contributing to this figure rising to a projected $30.04bn, according to GlobalData analysis.

In addition, more than $15.48bn in pharma sales were recorded in Mexico in 2021, and the country offers a strong manufacturing base for antibiotics, analgesics, and antiparasitics. Furthermore, the Mexican market typically favors branded products over generics, making the country a highly suitable location to license innovative medicines.

And there are numerous opportunities for pharma companies in Mexico. When it comes to core health services, an estimated 90% of Mexico’s population of 128.9 million has coverage. However, out-of-pocket payments make up more than 40% of total healthcare spending in the country.

Making the Mexican pharma market more competitive

Mexico is increasingly attracting international pharma companies and contract manufacturers. Recent government interventions have helped make the country more competitive in the R&D of new drugs and the biosimilars market, as two examples, according to GlobalData. Then there is the rapidly growing market of medical tourism, with estimates suggesting that treatments in Mexico are 30%-70% cheaper than in the US.

One challenge the Mexican Government has made a priority is stamping out historic issues such as alleged corruption and accusations that public funds are being misused. The intention is that this action will increase transparency and improve confidence among international investors. The national government is also taking action to resolve issues regarding the supply chain and regulations. Additionally, to address ongoing shortages of medicine in the country, the government has changed the processes by which medicines are acquired in a bid to improve matters.

Furthermore, a significant change was announced in August 2020. The Federal Commission for the Protection Against Sanitary Risks Comisión Federal de Protección contra Riesgos Sanitarios (COFEPRIS) unveiled plans to speed up the approval process for generics and biosimilars in Mexico. The plans enable drug manufacturers to file for registration of generics and biosimilars the next day after patent approval is granted for the originator drug. These changes can potentially cut years from the approval time for generics and biosimilars, with government investments also enhancing Mexico’s self-sufficiency in this key pharma segment.

Mexico has also been working to publish its National Pharmaceutical Policy (PNF), with the intention to boost and support nationwide scientific research, while also encouraging innovation in pharmaceuticals.

Proof that this strategy is taking effect is in the significant amount of international pharma companies and CROs with operations in the country. GlobalData estimates that just under half of all companies involved in pharmaceuticals in Mexico have overseas owners, attracted by manufacturing costs that are 17 times lower than in the US, according to 2018 figures. 

Mexican pharma market

Attracting international investments in pharma

Mexico is fast becoming one of the most promising global destinations for pharmaceutical investments, with contributing factors that include a middle-class population that is already large and also growing, a favorable environment for the private sector, and an increase in demand for healthcare services nationally.

Mexico is a particularly appealing location for foreign investments, thanks to its lower costs for manufacturing and clinical trials, as well as its closeness to the US – the largest pharma market in the world. Doctors and patients are often familiar with new therapies being developed in both countries and are keen to gain access.

In fact, the majority of foreign direct investment in Mexico comes from the US. The appeal of Mexico for US investors has increased in recent years, driven by efforts to lessen the dependence on China.

Disruption to the supply chain caused by Covid-19 has been another factor in US companies opting to bring manufacturing activities nearer to their main base of operations. North American neighbor Canada is also making the most of what the Mexican pharma market offers for operations. 

Clinical trials in Mexico

Regarding clinical trials, GlobalData reports that 763 were held in Mexico between January 2019 and February 2022. In terms of therapy areas, most trials in this region have been in the infectious disease segment during the last three years, driven in part by demand for the development of a Covid-19 vaccine. This is followed by oncology. As for indications, infectious diseases make up the bulk of clinical trials, with autoimmune disorders and diabetes following some way behind.

Large pharma industry players are reportedly represented significantly more than domestic companies in the category of top clinical trial sponsors in Mexico.

With a large population supplementing high recruitment rates, competitive market costs, a high level of specialization across the clinical research phases and other key advantages, Mexico is a region worth considering for companies involved in clinical research.  

Welcome to Cohortias!

The CRO
of Latin America

Simplify Your Clinical Trials with Our Expert Infrastructure in Latin America

Say goodbye to the complex, costly, and disorganized process of conducting clinical trials. Our infrastructure in Latin America streamlines the launch of studies and ensures adherence to international standards. Schedule a call with us today to discover the path to simplified clinical research in Latin America.

mexican pharma market,cro of latam

Explore What We Are Doing Better

We define ourselves as a unique team, capable of blending our academic background with a global business mindset to bring the highest standard of quality and operational excellence into clinical research in Latin America.

Early Phase Trials

- First-in-Human Studies.
- Get to patients faster, no IND necessary.
- Valid data for FDA submission.

Rescue Studies

- Regain lost time and boost patient recruitment.
- We work alongside Global CROs to get studies back on track.
- More than 200 sites available.

Phase II & III Trials

- Full-Service Clinical Outsourcing.
- Proven infrastructure that can handle any trial.
- Local Regulatory Experts
- Wide network of sites and physicians.

Medical Devices

- A fast-track platform that will meet your timeline.
- We take care of everything, from shipping requirements all the way to data collection.
mexican pharma market,cro of latam

Full Service CRO in LATAM

Outsourcing Clinical Trials to Latin America

Unlock the advantages and opportunities of outsourcing clinical trials to Latin America. Diverse patient population, streamlined regulations, and cost-effectiveness

Lower Operating Costs

From lower labor costs to lower costs for rent, utilities, and equipment, you can save money on your clinical trial budget while still ensuring the quality of your trial

Access to Emerging Markets

Latin America offers access to emerging markets, providing an opportunity for pharmaceutical companies to expand their reach and reach new patient populations.

mexican pharma market,cro of latam

Cohortias is redefining Clinical Research in Latin America

We are committed to become leaders in providing clinical research services in Latin America. Here at Cohortias, we combine our academic roots, proven experience and a large pool of patients from an extensive network of sites.

Our main purpose is to deliver high quality data.

mexican pharma market,cro of latam

Clinical Research in Latin America

Cohortias has built an extensive and highly reputable network of clinical sites which can access patients in a timely manner and operate within a standard-of-care comparable to the U.S. healthcare system.

CLINICAL DEVELOPMENT

  • Site Management

  • Data Management

  • Site Selection

  • Regulatory Submissions

  • Clinical Monitoring

  • Protocol Development

CLINICAL TRIAL SERVICES

Beta Trials Platform

  • First-in-human studies

Medical Devices

  • Pilot and Pivotal Device Studies

Phases I – III

  • We partner with our clients to bring their products in a fast and efficient manner to the market with the highest quality standards

MAIN THERAPEUTIC AREAS

  • Diabetes/Metabolic Syndromes
  • Infectious Diseases
  • Cardiovascular
  • Neurology
  • Respiratory
  • Oncology

mexican pharma market,cro of latam

Clinical Research in Latin America

Academic Leadership and Extensive Clinical Site Network for Efficient Clinical Trials

  • Our peer-to-peer management approach guarantees high patient recruitment and retention in any clinical trial

High Speed Execution

  • We offer the quickest start-up times in each country.
  • Efficient Clinical Site Selection and Contracting.
  • Benefit from our extensive network of clinical sites and streamlined contracting process.

Operational Excellence

  • Proven record of delivering rescue studies, we consistently exceed industry performance standards.
  • Our team provides efficient query resolution to keep your trial on track.

Business Insight and Flexibility

  • We offer innovative pricing models and short lines of communication to ensure maximum flexibility and cost-effectiveness.
  • At Cohortias, we prioritize  short lines of communication to ensure efficient collaboration.
  • Swift adaptation to changes in the trial landscape to keep your study on schedule.

mexican pharma market,cro of latam

We provide our services with offices in:

Argentina,
Brazil,
Colombia &
Mexico.

Daniela Maresca
Daniela Maresca | Country Lead Argentina
Martín Hernández-Torre | CMO
Maritza Rojas | CRA II
Pedro Alvarez | Business Development Manager
Samantha Rodriguez Cohortias
Samantha Rdz. | Start-Up Manager
mexican pharma market,cro of latam

The Cohortias Team

mexican pharma market,cro of latam

As the largest South American Contract research Organization, we know the Advantages and Challenges Of the Region

Let Us Guide You Through The Latin American Clinical Research Landscape

mexican pharma market,cro of latam

Network & Partnerships